 |
|
Enzyme may hold key to improved targeting of cancer-fighting drugs
May 30, 2008Latest research points to new compounds and improved control
CHESTNUT HILL, MA - A critical enzyme used to prepare a powerful cancer-killing agent may be able to help drug makers better target the cells the natural product attacks, according to findings published in the May 23 edition of the Journal of Biological Chemistry.
Building on their earlier research into neocarzinostatin, a team of researchers from Boston College and the University of Wisconsin, Madison discovered that one of the enzymes contained in the bacteria used to produce the drug may hold promise in creating newer, more stable compounds from the structurally complex class of antibiotic known as chromoproteins.
"We've revealed that the enzyme is loose in specificity, which means it may be able to be used to make new drugs," said Boston College Chemist Steven D. Bruner, a co-author of the report. "Based on these findings, we foresee success in the lab making certain compounds more controllable."
In addition to Bruner, the research team includes BC graduate student Heather A. Cooke and University of Wisconsin Professor Ben Shen and researchers Yinggang Luo, Shuangjun Lin and Jian Zhang.
Used as a chemotherapeutic, the drug - an enediyne anti-tumor agent - targets both normal and cancer cells, says Bruner, an assistant professor of chemistry. But the team has determined that the chemical components of the antibiotic are capable of distinguishing between normal cells and cancer cells.
The latest research confirmed the team's proposal that the naphthoic acid within the compound can be altered to design cancer-fighting drugs specific to chemotherapeutic targets. That will require the use of genetic engineering in order to manipulate the molecules within the bacteria, which occurs naturally in soil.
Genetic engineering will enable researchers to produce more specific and less toxic analogs of neocarzinostatin and increase the available supply of the drug, Bruner says.
"This is the beginning of an approach to be able to understand and manipulate these chemical pathways to make new drugs," says Bruner.
Boston College
"We've revealed that the enzyme is loose in specificity, which means it may be able to be used to make new drugs," said Boston College Chemist Steven D. Bruner, a co-author of the report. "Based on these findings, we foresee success in the lab making certain compounds more controllable."
In addition to Bruner, the research team includes BC graduate student Heather A. Cooke and University of Wisconsin Professor Ben Shen and researchers Yinggang Luo, Shuangjun Lin and Jian Zhang.
Used as a chemotherapeutic, the drug - an enediyne anti-tumor agent - targets both normal and cancer cells, says Bruner, an assistant professor of chemistry. But the team has determined that the chemical components of the antibiotic are capable of distinguishing between normal cells and cancer cells.
The latest research confirmed the team's proposal that the naphthoic acid within the compound can be altered to design cancer-fighting drugs specific to chemotherapeutic targets. That will require the use of genetic engineering in order to manipulate the molecules within the bacteria, which occurs naturally in soil.
Genetic engineering will enable researchers to produce more specific and less toxic analogs of neocarzinostatin and increase the available supply of the drug, Bruner says.
"This is the beginning of an approach to be able to understand and manipulate these chemical pathways to make new drugs," says Bruner.
Boston College
Fighting cancer with aspirin?
When looking for new weapons in the war on cancer, scientists should turn to their medicine cabinets for an age-old remedy-aspirin. According to scientists at the University of Newcastle (UK), aspirin has cancer-fighting effects that extend beyond already understood Cox inhibitors.
Cell-regulating gene may predict survival outcomes for breast cancer patients
A study led by researchers at Mount Sinai School of Medicine has shown that a cell-regulating gene overexpressed in about 30 to 50 percent of all breast cancers is associated with a better chance of survival and increased sensitivity to a cancer-fighting drug.
Tweaking Taxol points way to a greener, more productive future
As the effective cancer-treatment drug Taxol enters its next generation, Michigan State University announces discoveries which point to both environmentally friendly ways to produce more Taxol, and ultimately innovations to produce a more potent second-generation drug.
More Cancer-fighting Drug News Articles
| Fighting the good fight.(SKIN CANCER FOUNDATION UPDATE): An article from: Journal of Drugs in Dermatology This digital document is an article from Journal of Drugs in Dermatology, published by Thomson Gale on January 1, 2006. The length of the article is 676 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
| Firm looks to the ocean to fight cancer: Nereus Pharmaceuticals gets $42.6 million shot in the arm.(ocean-derived microorganisms into cancer-fighting drugs): ... An article from: San Diego Business Journal by Marion Webb This digital document is an article from San Diego Business Journal, published by CBJ, L.P. on January 10, 2005. The length of the article is 818 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:... |
| © 2008 BrightSurf.com |